Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating hypertension and cardiovascular disease

A composition and cardiovascular technology, applied in the field of medicine, can solve problems such as low blood pressure, failure to consider the law of blood pressure changes in patients, and unsatisfactory blood pressure control, so as to increase the level of bradykinin, eliminate adverse reactions, and avoid photolysis. Effect

Inactive Publication Date: 2006-12-27
CSPC OUYI PHARM CO LTD
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The traditional method of taking medicine three times a day does not consider the patient's blood pressure change pattern, but only considers lowering blood pressure blindly. As a result, the blood pressure control in the morning is not ideal, and the blood pressure is often low in the afternoon and night

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating hypertension and cardiovascular disease
  • Pharmaceutical composition for treating hypertension and cardiovascular disease
  • Pharmaceutical composition for treating hypertension and cardiovascular disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-10

[0022] The dosage forms of the pharmaceutical compositions of Examples 1 to 10 are tablets, and the raw material formulations of each example are the amount for preparing 1000 tablets. The raw material formula of embodiment 1 to embodiment 10 is provided by table 1.

[0023] The preparation method of Examples 1 to 10: Grind levoamlodipine salt, angiotensin-converting enzyme inhibitor, corresponding cyclodextrin and water efficiently and rapidly for 1 hour, then dry in vacuum at 400°C, pulverize, pass through a 1000-mesh sieve, Then add the remaining materials, mix in a mixer for 10 minutes, press into tablets, and pack after passing the test.

[0024] Usage: take orally, once a day, one tablet each time, take it in the morning.

Embodiment 11-13

[0026] The dosage forms of the pharmaceutical compositions of Examples 11 to 13 are capsules, and the raw material formulations of each example are the amount of medicine in 1000 capsules. The raw material formula of embodiment 11 to embodiment 13 is provided by table 2.

[0027]The preparation method of Examples 11 to 13: levamlodipine salt, benazepril (or enalazepril), cyclodextrin and water are efficiently and rapidly ground for 1 hour, then dried in vacuum at 400° C., pulverized, and passed through 1000 auto Sieve, then add the remaining materials, mix with a mixer for 10 minutes, pack into capsules, and pack after passing the test.

[0028] Usage: Take it orally, once a day, one capsule each time, in the morning.

Embodiment 14-16

[0030] The dosage forms of the pharmaceutical compositions of Examples 14 to 16 are injections, and the raw material formulations of each example are the amount for preparing 100 sterile injections. The raw material formula of embodiment 14 to embodiment 16 is provided by table 3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for treating hypertension and other cardiovascular diseases, wherein the active constituents include pharmaceutical salts of levamlodipine besylate and angiotensin converting enzyme inhibitor. The invention can not only overcome the drawback of photodecomposition of the levoamlodipine maleate medicaments, but also can increase the dissolving degree by 25%.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating hypertensive cardiovascular disease, belonging to the technical field of medicine. Background technique [0002] Hypertension is the most common cardiovascular disease in the world, and it is also one of the largest epidemics. It often causes complications in the heart, brain, kidney and other organs, and seriously endangers human health. Early prevention and timely treatment are extremely important. Then research and development of drugs for the treatment of cardiovascular diseases has become one of the hot spots in the field of medical research. [0003] In the treatment of hypertension, Pfizer's "Norvasc", ie amlodipine besylate, is widely used in clinical practice. It is a new generation of calcium antagonist, which is recognized as a safe and effective antihypertensive drug by the US FDA. Amlodipine is a new generation of long-acting, basic dihydropyridine calcium channel antago...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4422A61K45/06A61K9/20A61K9/48A61P9/12A61K31/40
Inventor 郭卫芹李国聪张育高志峰
Owner CSPC OUYI PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com